A Houston company has joined a new Amazon program focused on Latin American founders. Photo courtesy of Amazon

Amazon named the 20 startups joining its accelerator that will connect Latinx founders to its network of mentors, provide programming, and even dole out funding.

The AWS Impact Accelerator Latino Founders Cohort is a part of Amazon's $30 million commitment to supporting underrepresented startup founders. The eight-week program started this week in Amazon's Seattle headquarters.

“This cohort of the AWS Impact Accelerator aims to highlight the viability and ingenuity of Latino-led startups, so the VC community can increase support to these founders,” says Howard Wright, vice president and global head of startups at AWS, in the news release. “We’re looking forward to playing an active role in helping these companies turbocharge their growth through access to capital, experts, and all of the innovations that the AWS tech stack has to offer.”

Houston-based Ease, founded by Mario Amaro in 2018, the health care fintech platform allows for medical professionals to start, grow, and manage their private practices with bookkeeping tools and other software infrastructure. So far, the company has worked with more than 300 practices. Per Cruncbase data, the company has raised $2.8 million in pre-seed and grant funding. According to Amazon, the company's investors include Slauson & Co. and Precursor Ventures.

Mario Amaro, founder of Ease, was selected for one of Amazon's accelerator programs. Photo courtesy of Amazon

Last year, Ease was named among the 50 companies in the inaugural cohort of the Google for Startups Latino Founders Fund. In that program, each company received an equity-free $100,000 investment, as well as programming and support from Google, mentorship from technical and business experts, access to free mental health therapy, and more.

Ease stood out among the nearly 1,100 submissions to the program, according to the release, and joins 19 other companies from across the country and even Argentina, Brazil, Colombia, Mexico, Venezuela, and Puerto Rico. Each of the cohort companies will receive up to $225,000 in cash and AWS Activate credits, alongside a training curriculum, networking opportunities with Amazon staff and potential investors, and ongoing advisory support.

The other startups in the program include:

  • Alvva, a, immigrant-focused fintech platform from California
  • Cogniflow, a personal AI platform founded in Colombia with a New York US HQ
  • Deskfy, a marketing portal from Brazil with its US HQ in Delaware
  • DivySci Software, an edtech organization founded in New York
  • EducUp, an edtech company from Florida
  • Fielder, a Mexico-founded enterprise software-as-a-service with US-based operations in Delaware
  • GamerSafer, a security tech company within gaming from California
  • Kigüi, a Mexican money-saving grocery app
  • Kuentro, a Venezuelan affordable hiring platform that caters to middle- and working-class job seekers
  • Lazo Fintech Inc, a Florida-based fintech and legal platform
  • Leantime, a developer tool from North Carolina
  • Monadd, a Florida-founded personal finance platform
  • PilotoMail, a remote work platform founded in Puerto Rico
  • Sign-Speak, a New York startup with an American Sign Language device
  • STIGMA, a mental health mobile app from Illinois
  • Outtrip, a Argentina-founded tourism platform with US operations in Delaware
  • Panda Salud, a Mexico-based platform connecting health care small businesses with diagnostic test providers
  • Tienditapp, a Mexico-based app with a last-mile delivery model
  • TuCuota, a payment collections tool from Argentina
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers: Here's what it takes to spot a great new idea

houston voices

Having a “promotion focus” really does create a mental lens through which new ideas are more visible.

Key findings:

  • New ideas can be crucially important to businesses, driving innovation and preventing stagnation.
  • Recognizing those ideas, though, isn’t always easy.
  • Nurturing what is known as “promotion focus” can help managers spot fresh ideas.

Whenever the late surgeon Michael DeBakey opened a human chest, he drew on a lifetime of resources: the conviction that heart surgery could and should be vastly improved, the skill to venture beyond medicine’s known horizons and the vision to recognize new ideas in everyone around him, no matter how little formal training they had.

Appreciating new ideas is the heartbeat of business as well as medicine. But innovation is surprisingly hard to recognize. In a pioneering 2017 article, Rice Business Professor Jing Zhou and her colleagues published their findings on the first-ever study of the traits and environments that allow leaders to recognize new ideas.

Recent decades have produced a surge of research looking at how and when employees generate fresh ideas. But almost nothing has been written on another crucial part of workplace creativity: a leader’s ability to appreciate new thinking when she sees it.

Novelty, after all, is what drives company differentiation and competitiveness. Work that springs from new concepts sparks more investigation than work based on worn, already established thought. Companies invest millions to recruit and pay star creatives.

Yet not every leader can spot a fresh idea, and not every workplace brings out that kind of discernment. In four separate studies, Zhou and her coauthors examined exactly what it takes to see a glittering new idea wherever it appears. Their work sets the stage for an entirely new field of future research.

First, though, the team had to define their key terms. “Novelty recognition” is the ability to spot a new idea when someone else presents it. “Promotion focus,” previous research has shown, is a comfort level with new experiences that evokes feelings of adventure and excitement. “Prevention focus” is the opposite trait: the tendency to associate new ideas with danger, and respond to them with caution.

But does having “promotion focus” as opposed to “prevention focus” color the ability to see novelty? To find out, Zhou’s team came up with an ingenious test, artificially inducing these two perspectives through a series of exercises. First, they told 92 undergraduate participants that they would be asked to perform a set of unrelated tasks. Then the subjects guided a fictional mouse through two pencil and paper maze exercises.

While one exercise showed a piece of cheese awaiting the mouse at the end of the maze (the promise of a reward), the other maze depicted a menacing owl nearby (motivation to flee).

Once the participants had traced their way through the mazes with pencils, they were asked to rate the novelty of 33 pictures — nine drawings of space aliens and 24 unrelated images. The students who were prepped to feel an adventurous promotion focus by seeking a reward were much better at spotting the new or different details among these images than the students who’d been cued to have a prevention focus by fleeing a threat.

The conclusion: a promotion focus really does create a mental lens through which new ideas are more visible.

Zhou’s team followed this study with three additional studies, including one that surveyed 44 human resource managers from a variety of companies. For this study, independent coders rated the mission statements of each firm, assessing their cultures as “innovative” or “not innovative.” The HR managers then evaluated a set of written practices — three that had been in use for years, and three new ones that relied on recent technology. The managers from the innovative companies were much better at rating the new HR practices for novelty and creativity. To recognize novelty, in other words, both interior and external environments make a difference.

The implications of the research are groundbreaking. The first ever done on this subject, it opens up a completely new research field with profound questions. Can promotion focus be created? How much of this trait is genetic, and how much based on natural temperament, culture, environment and life experience? Should promotion focus be cultivated in education? If so, what would be the impact? After all, there are important uses for prevention focus, such as corporate security and compliance. Meanwhile, how can workplaces be organized to bring out the best in both kinds of focus?

Leaders eager to put Zhou’s findings to use right away, meanwhile, might look to the real-world model of Michael DeBakey. Practice viewing new ideas as adventures, seek workplaces that actively push innovation and, above all, cultivate the view that every coworker, high or low, is a potential source of glittering new ideas.

---

This article originally appeared on Rice Business Wisdom.

Jing Zhou is the Mary Gibbs Jones Professor of Management and Psychology in Organizational Behavior at the Jones Graduate School of Business of Rice University. Zhou, J., Wang, X., Song, J., & Wu, J. (2017). "Is it new? Personal and contextual influences on perceptions of novelty and creativity." Journal of Applied Psychology, 102(2): 180-202.

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”